Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of ¹⁷⁷Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells

• Main Authors: Rashmi G. Shah, Marine A. Merlin, Samuel Adant, Fayçal Zine-Eddine, Jean-Mathieu Beauregard, Girish M. Shah
• Format: Article
• Language: English
• Published: MDPI AG 2021-01-01
• Series: Cancers
• Subjects: NETs: neuroendocrine tumors; SSTR: somatostatin receptors; PRRT: peptide receptor radionuclide therapy; LuTate: ¹⁷⁷Lu-DOTA-octreotate; chemotherapy
• Online Access: https://www.mdpi.com/2072-6694/13/2/232

The peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-DOTA-octreotate (LuTate) is recommended for different types of neuroendocrine tumors (NETs) which overexpress somatostatin receptors (SSTR). A combination with chemotherapy improves objective response to LuTate in NET patients and here we characterized chemotherapy-induced upregulation of SSTR2 receptors as a cause for this improved response to LuTate. The NET cell lines with low (BON-1) or relatively high (NCI-H727) SSTR2-expression levels, and non-NET cancer and normal cells were treated with chemotherapeutic drugs and assessed for upregulation of SSTR2. We report that an exposure to low or high doses of drugs, such as temozolomide for 24 h or 5 day results in upregulation of SSTR2 between 3–7 days, increased LuTate uptake and decreased rate of cell proliferation. This effect is at the level of SSTR2-mRNA and is more pronounced in low SSTR2 expressing BON-1 than in high SSTR2 expressing NCI-H727 or non-NET cancer or normal cells. Thus, a properly timed pre-treatment with low-dose chemotherapy could not only improve therapeutic efficacy of LuTate in NET patients who are presently eligible for PRRT, but also allow PRRT to be administered to patients with low SSTR-expressing NETs, who would otherwise not respond to this modality because of insufficient radiation delivery.